SCHEMBL8919196

SCHEMBL8919196

COc1cc(C(=O)O)cc2ccc(=O)[nH]c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA4 P22748 2/20 0.50
CA6 P23280 2/20 0.50
CA7 P43166 2/20 0.50
CA9 Q16790 2/20 0.50
CA14 Q9ULX7 2/20 0.50
CA3 P07451 1/20 0.50
PKM P14618 1/20 0.50
CA5A P35218 1/20 0.50
CA5B Q9Y2D0 1/20 0.50
TPMT P51580 2/20 0.49
PTGS2 P35354 1/20 0.47
CNR2 P34972 2/20 0.46
KDM4E B2RXH2 3/20 0.46
HTT P42858 2/20 0.46
HPGD P15428 2/20 0.45
LMNA P02545 3/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19945392 0.84 ALDH1A1 (0.48) KDM4EHPGDLMNAALDH1A1CYP3A4
SCHEMBL8920575 0.81 HSD17B2 (0.52) CA12CA1CA2CA7CA9
SCHEMBL24988168 0.81 KMT2A (0.39) CA12CA1CA4CA6CA7
SCHEMBL1144962 0.81 MEN1 (0.41) CA12CA9TPMTKDM4EHPGD
SCHEMBL15971548 0.79 CA12 (0.51) CA12CA1CA2CA4CA6
SCHEMBL8921146 0.78 DAO (0.41) KDM4EHPGDALDH1A1RAB9A
SCHEMBL18032995 0.78 CA12 (0.53) CA12CA1CA2CA4CA6
SCHEMBL8919071 0.77 EIF4A3 (0.54) KDM4EHPGDALDH1A1
SCHEMBL19751536 0.77 CA12 (0.49) CA12CA9LMNA
SCHEMBL28427455 0.77 CA12 (0.44) CA12CA9CNR2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11021444-B2 Antiviral compounds Janssen Biopharma, Inc. (US) 2021-06-01 US disclosed
US-20190263754-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. (US) 2019-08-29 US disclosed
US-20180065932-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2018-03-08 US disclosed
US-20150065504-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2015-03-05 US disclosed
US-5591751-A CARBOSTYRIL DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-01-07 US disclosed
EP-0636128-A1 PIPERAZINOCARBONYLCARBOSTYRILS AS PERIPHERAL VASODILATORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-02-01 EP disclosed
WO-1994019339-A1 PIPERAZINOCARBONYLCARBOSTYRILS AS PERIPHERAL VASODILATORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190263754-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 CA12 4108/4885CA1 4791/4885CA2 3830/4885
US-11021444-B2 Antiviral compounds MAVS, SARS1, ZC3HAV1 CA12 4108/4885CA1 4791/4885CA2 3830/4885
US-20180065932-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 CA12 4108/4885CA1 4791/4885CA2 3830/4885
US-20150065504-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 CA12 4108/4885CA1 4791/4885CA2 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.